Telo Genomics Reports Positive Interim Data for 3D Telomere-Based Relapse Risk Assay in Multiple Myeloma
核心洞察
Telo Genomics (搜索) announced positive interim results from a retrospective clinical study evaluating its 3D telomere profiling platform in 50 multiple myeloma (搜索) patients with known two-year outcomes.
The assay achieved an AUC of 0.849 in ROC analysis, with "Average Distance to Nuclear Center" emerging as the strongest predictor of relapse status.
The blood-based platform aims to combine MRD detection, malignant cell identification, and relapse-risk prognostication within a single liquid biopsy assay.
Telo Genomics (搜索) Corp. has announced positive interim data from an ongoing retrospective clinical study evaluating its proprietary 3D telomere profiling platform for relapse risk assessment in multiple myeloma (搜索). The study, conducted in collaboration with the National and Kapodistrian University of Athens, analyzed baseline blood samples from 50 multiple myeloma patients with known two-year clinical outcomes, enabling direct comparison between patients who relapsed and those who remained in remission.
The interim analysis identified "Average Distance to Nuclear Center," a telomere-associated nuclear architecture parameter linked to genomic instability, as the strongest predictor of relapse status. Receiver Operating Characteristic (ROC) analysis demonstrated strong discriminatory performance, with the assay achieving an Area Under the Curve (AUC) of 0.849 — a level considered highly predictive in clinical diagnostics.
"These interim results support our belief that telomere-driven genomic instability analysis may provide clinicians with a fundamentally new way to assess relapse risk in multiple myeloma (搜索)," said John Farlinger, CEO and Chairman of Telo Genomics (搜索). "Current monitoring approaches are valuable for measuring disease burden, but do not fully address the challenge of identifying which patients are most likely to experience relapse."
Differentiating from Existing MRD Technologies
The Telo Genomics (搜索) platform addresses what the company describes as a key limitation of current minimal residual disease (MRD) technologies. While Next-Generation Flow (NGF) and Next-Generation Sequencing (NGS) primarily measure residual disease burden, the Telo Genomics approach combines highly sensitive circulating tumor cell (CTC) detection with single-cell 3D telomere profiling to assess the genomic instability and biologic behavior of residual tumor cells.
"Current MRD approaches, including EuroFlow-based next-generation flow cytometry and Adaptive Biotechnologies' ClonoSEQ (搜索)® assay, provide valuable information regarding residual disease burden, but are not designed to assess the biological characteristics that may drive future relapses," said Dr. Sabine Mai, Co-Founder and Director of Telo Genomics (搜索). "By evaluating genomic instability through three-dimensional telomere organization at the single-cell level, our platform may provide prognostic insight into relapse risk that complements existing MRD methodologies."
The interim results suggest several clinical and technological capabilities: telomere-driven nuclear architecture patterns may serve as predictive biomarkers of relapse risk; the platform may identify biologically aggressive disease not apparent through conventional residual disease measurements; the assay may combine residual disease detection and relapse-risk stratification within a single test; serial 3D telomere profiling may enable monitoring of disease evolution over time; and blood-based testing may reduce dependence on repeated bone marrow sampling.
To the Company's knowledge, no clinically implemented MRD scoring model currently integrates residual disease detection with single-cell genomic-instability profiling to predict relapse risk in this manner.
Additional Validation Studies Underway
Beyond the Athens study, Telo Genomics (搜索) has partnered with the Cleveland Clinic and Montreal Jewish General Hospital to analyze MRD in a cumulative cohort of approximately 20 multiple myeloma (搜索) patients, with blood and bone marrow samples collected from different stages of treatment progression. The company previously demonstrated an analytical limit of detection of one tumor cell per 10 million white blood cells, published in BioTechniques (PMID: 41873241).
The current study is designed to directly compare Telo Genomics (搜索)' ability to isolate and characterize circulating tumor cells from peripheral blood against NGS-based MRD results generated by Adaptive Biotechnologies' ClonoSEQ (搜索)®. In addition to MRD status assessment, the study incorporates serial three-dimensional telomere profiling of circulating tumor cells, enabling longitudinal monitoring of both MRD status and genomic instability over time to evaluate how changes in telomere architecture correlate with disease evolution, treatment response, and eventual clinical outcomes.
Telo Genomics (搜索) intends to continue validating its technology against current standards of care, including direct comparisons with EuroFlow, Adaptive, and other established MRD methodologies, with broader validation efforts expected through the end of 2026. The clinical trial in Athens is expected to conclude in summer 2026.
The company's lead application, Telo-MM (搜索), is being developed to provide actionable prognostic information to medical professionals treating multiple myeloma (搜索). The benefits of the proprietary 3D telomere technology have been substantiated in more than 190 peer-reviewed publications and over 30 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease.